{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:26:27Z","timestamp":1787840787486,"version":"build-2784847793"},"reference-count":114,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    Graves\u2019 orbitopathy (GO), a complex autoimmune disorder, remains the most common extrathyroidal manifestation of Graves\u2019 disease. Its pathogenesis is characterized by a progressive transition from inflammation to fibrosis, leading to debilitating ocular complications. While high-dose intravenous glucocorticoids have been the standard treatment for active moderate-to-severe GO, their lack of specificity to GO pathogenesis and limited efficacy in the fibrotic phase underscore the need for targeted therapies. This review explores emerging therapeutic targets in GO, focusing on pathways implicated in both inflammatory and fibrotic mechanisms. Teprotumumab, an insulin-like growth factor 1 receptor (IGF-1R) inhibitor, has revolutionized GO treatment, demonstrating clinical efficacy in reducing proptosis and inflammation. Interleukin-6 (IL-6) inhibitors including satralizumab are undergoing clinical trials. New studies on molecular pathways have been conducted regarding inflammation and fibrosis of GO, including platelet-derived growth factor\/fibroblast growth factor signaling, yes-associated protein 1\/transcriptional coactivator with PDZ-binding motif mechanotransduction, sphingosine-1-phosphate (S1P)\/S1P receptor axis, bone morphogenic protein 7, IL-11, IL-17 and microRNAs as well as, IGF-1R\/thyroid-stimulating hormone receptor crosstalk, and IL-6 trans-signaling. Most studies focus on exploring the potential of therapeutic agents through preclinical investigations but represent promising therapeutic avenues. Therapies targeting these pathways may offer a promising potential efficacy across the entire disease spectrum, from inflammation to fibrosis, thus overcome the limitations of conventional glucocorticoid therapy and expand therapeutic options in GO. Advances in\n                    <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                    GO models may bring forward a new era of GO treatment.\n                  <\/jats:p>","DOI":"10.4103\/tjo.tjo-d-25-00057","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T14:00:10Z","timestamp":1755180010000},"page":"58-67","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic targets for fibro-inflammation in Graves\u2019 orbitopathy"],"prefix":"10.4103","volume":"16","author":[{"given":"Young Jae","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Medicine, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sook","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"R1-20260325","doi-asserted-by":"crossref","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of graves'orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R2-20260325","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9394(14)72666-2","article-title":"The incidence of Graves'ophthalmopathy in Olmsted county, Minnesota","volume":"120","author":"Bartley","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"R3-20260325","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.beem.2011.09.004","article-title":"Prevention of Graves'ophthalmopathy","volume":"26","author":"Bartalena","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R4-20260325","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves'ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20260325","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves'orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R6-20260325","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1089\/thy.2007.0407","article-title":"Immune mechanisms in thyroid eye disease","volume":"18","author":"Lehmann","year":"2008","journal-title":"Thyroid"},{"key":"R7-20260325","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves'orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves'orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"R8-20260325","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1089\/thy.2023.0309","article-title":"Yes-associated protein mediates the transition from inflammation to fibrosis in graves'Orbitopathy","volume":"33","author":"Ko","year":"2023","journal-title":"Thyroid"},{"key":"R9-20260325","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12026-022-09267-y","article-title":"Research progress on drugs targeting the TGF-\u03b2 signaling pathway in fibrotic diseases","volume":"70","author":"Shi","year":"2022","journal-title":"Immunol Res"},{"key":"R10-20260325","doi-asserted-by":"crossref","first-page":"1062045","DOI":"10.3389\/fimmu.2023.1062045","article-title":"A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves'orbitopathy","volume":"14","author":"Cui","year":"2023","journal-title":"Front Immunol"},{"key":"R11-20260325","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves'disease aberrantly express the IGF-1 receptor:Implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol"},{"key":"R12-20260325","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors:A tale of two antigens implicated in Graves'disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"key":"R13-20260325","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1210\/en.2019-00055","article-title":"Arrestin-\u03b2-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk","volume":"160","author":"Krieger","year":"2019","journal-title":"Endocrinology"},{"key":"R14-20260325","doi-asserted-by":"crossref","first-page":"e1653","DOI":"10.1210\/clinem\/dgab824","article-title":"Inhibition of TSH\/IGF-1 receptor crosstalk by teprotumumab as a treatment modality of thyroid eye disease","volume":"107","author":"Krieger","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20260325","doi-asserted-by":"crossref","first-page":"31640","DOI":"10.1074\/jbc.273.48.31640","article-title":"beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor","volume":"273","author":"Lin","year":"1998","journal-title":"J Biol Chem"},{"key":"R16-20260325","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/thy.2018.0089","article-title":"Evidence that graves'ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors","volume":"28","author":"Marcus-Samuels","year":"2018","journal-title":"Thyroid"},{"key":"R17-20260325","doi-asserted-by":"crossref","first-page":"107502","DOI":"10.1016\/j.pharmthera.2020.107502","article-title":"TSH\/IGF1 receptor crosstalk:Mechanism and clinical implications","volume":"209","author":"Krieger","year":"2020","journal-title":"Pharmacol Ther"},{"key":"R18-20260325","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1210\/jc.2016-1315","article-title":"TSH\/IGF-1 receptor cross talk in graves'ophthalmopathy pathogenesis","volume":"101","author":"Krieger","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-20260325","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1096\/fj.13-231381","article-title":"IGF-1 receptor deficiency in thyrocytes impairs thyroid hormone secretion and completely inhibits TSH-stimulated goiter","volume":"27","author":"Ock","year":"2013","journal-title":"FASEB J"},{"key":"R20-20260325","doi-asserted-by":"crossref","first-page":"151902","DOI":"10.1016\/j.imbio.2019.151902","article-title":"Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy","volume":"225","author":"Paik","year":"2020","journal-title":"Immunobiology"},{"key":"R21-20260325","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/thy.2015.0254","article-title":"Forkhead transcription factor FOXO1 Is regulated by both a stimulatory thyrotropin receptor antibody and insulin-like growth factor-1 in orbital fibroblasts from patients with graves'Ophthalmopathy","volume":"25","author":"Kumar","year":"2015","journal-title":"Thyroid"},{"key":"R22-20260325","first-page":"6057589","article-title":"Insulin-like growth factor-1 signaling in lung development and inflammatory lung diseases","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed Res Int"},{"key":"R23-20260325","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1139\/bcb-2022-0199","article-title":"Mechanism of myocardial fibrosis regulation by IGF-1R in atrial fibrillation through the PI3K\/Akt\/FoxO3a pathway","volume":"101","author":"Zhang","year":"2023","journal-title":"Biochem Cell Biol"},{"key":"R24-20260325","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.3748\/wjg.v20.i16.4648","article-title":"Resveratrol inhibits collagen I synthesis by suppressing IGF-1R activation in intestinal fibroblasts","volume":"20","author":"Li","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R25-20260325","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1096\/fj.201901719RR","article-title":"IPF pathogenesis is dependent upon TGF\u03b2 induction of IGF-1","volume":"34","author":"Hernandez","year":"2020","journal-title":"FASEB J"},{"key":"R26-20260325","doi-asserted-by":"crossref","first-page":"e0150418","DOI":"10.1371\/journal.pone.0150418","article-title":"miR-130b-3p modulates epithelial-mesenchymal crosstalk in lung fibrosis by targeting IGF-1","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"R27-20260325","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41419-021-03965-5","article-title":"IGF-1 protects against angiotensin II-induced cardiac fibrosis by targeting \u03b1SMA","volume":"12","author":"Ock","year":"2021","journal-title":"Cell Death Dis"},{"key":"R28-20260325","doi-asserted-by":"crossref","first-page":"126263","DOI":"10.1016\/j.ijbiomac.2023.126263","article-title":"Effects and potential mechanisms of IGF1\/IGF1R in the liver fibrosis:A review","volume":"251","author":"Gui","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"R29-20260325","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"R30-20260325","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"R31-20260325","first-page":"101464","article-title":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","volume":"55","author":"Hiromatsu","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"R32-20260325","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease:A pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R33-20260325","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/bph.13693","article-title":"Inhibiting thyrotropin\/insulin-like growth factor 1 receptor crosstalk to treat Graves'ophthalmopathy:Studies in orbital fibroblasts in vitro","volume":"174","author":"Place","year":"2017","journal-title":"Br J Pharmacol"},{"key":"R34-20260325","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"key":"R35-20260325","doi-asserted-by":"crossref","first-page":"E400","DOI":"10.1210\/jc.2011-2697","article-title":"Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves'ophthalmopathy","volume":"97","author":"van Steensel","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-20260325","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000367968","article-title":"Platelet-derived growth factor:A key factor in the pathogenesis of graves'ophthalmopathy and potential target for treatment","volume":"3","author":"Virakul","year":"2014","journal-title":"Eur Thyroid J"},{"key":"R37-20260325","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1167\/iovs.09-4338","article-title":"Platelet-derived growth factor-BB:A stimulus for cytokine production by orbital fibroblasts in Graves'ophthalmopathy","volume":"51","author":"van Steensel","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R38-20260325","doi-asserted-by":"crossref","first-page":"E944","DOI":"10.1210\/jc.2012-1020","article-title":"PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves'ophthalmopathy patients","volume":"97","author":"van Steensel","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-20260325","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1167\/iovs.08-2443","article-title":"Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts:A potential treatment for Graves'ophthalmopathy","volume":"50","author":"van Steensel","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R40-20260325","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"R41-20260325","doi-asserted-by":"crossref","first-page":"e95586","DOI":"10.1371\/journal.pone.0095586","article-title":"Independent adipogenic and contractile properties of fibroblasts in Graves'orbitopathy:An in vitro model for the evaluation of treatments","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"R42-20260325","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00417-014-2674-7","article-title":"The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation","volume":"252","author":"Virakul","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R43-20260325","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family:Biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"R44-20260325","doi-asserted-by":"crossref","first-page":"e0255344","DOI":"10.1371\/journal.pone.0255344","article-title":"Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves'orbitopathy","volume":"16","author":"Jang","year":"2021","journal-title":"PLoS One"},{"key":"R45-20260325","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/thy.2018.0544","article-title":"Basic fibroblast growth factor induces adipogenesis in orbital fibroblasts:Implications for the pathogenesis of graves'orbitopathy","volume":"29","author":"Schrijver","year":"2019","journal-title":"Thyroid"},{"key":"R46-20260325","doi-asserted-by":"crossref","first-page":"412158","DOI":"10.1155\/2014\/412158","article-title":"Markers of inflammation and fibrosis in the orbital fat\/connective tissue of patients with Graves'orbitopathy:Clinical implications","volume":"2014","author":"Pawlowski","year":"2014","journal-title":"Mediators Inflamm"},{"key":"R47-20260325","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00417-014-2662-y","article-title":"Increased serum VEGF and b-FGF in Graves'ophthalmopathy","volume":"252","author":"Ye","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R48-20260325","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.mce.2016.05.023","article-title":"Basic FGF and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts","volume":"433","author":"Virakul","year":"2016","journal-title":"Mol Cell Endocrinol"},{"key":"R49-20260325","first-page":"1085","article-title":"Topical application of a new monoclonal antibody against fibroblast growth factor 10 (FGF 10) mitigates propranolol-induced psoriasis-like lesions in guinea pigs","volume":"18","author":"Yao","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R50-20260325","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1002\/mco2.340","article-title":"YAP\/TAZ:Molecular pathway and disease therapy","volume":"4","author":"Wei","year":"2023","journal-title":"MedComm (2020)"},{"key":"R51-20260325","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ncb2303","article-title":"The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal","volume":"13","author":"Zhao","year":"2011","journal-title":"Nat Cell Biol"},{"key":"R52-20260325","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10137","article-title":"Role of YAP\/TAZ in mechanotransduction","volume":"474","author":"Dupont","year":"2011","journal-title":"Nature"},{"key":"R53-20260325","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.3390\/cells11132065","article-title":"New insights into Hippo\/YAP signaling in fibrotic diseases","volume":"11","author":"Mia","year":"2022","journal-title":"Cells"},{"key":"R54-20260325","doi-asserted-by":"crossref","first-page":"1204033","DOI":"10.3389\/fcell.2023.1204033","article-title":"YAP at the progression of inflammation","volume":"11","author":"Chen","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"R55-20260325","doi-asserted-by":"crossref","first-page":"L344","DOI":"10.1152\/ajplung.00300.2014","article-title":"Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis","volume":"308","author":"Liu","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R56-20260325","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/cancers13153812","article-title":"A yes-associated protein (YAP) and insulin-like growth factor 1 receptor (IGF-1R) signaling loop is involved in sorafenib resistance in Hepatocellular Carcinoma","volume":"13","author":"Ngo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R57-20260325","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41418-018-0250-0","article-title":"YAP1\/twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF","volume":"26","author":"Chen","year":"2019","journal-title":"Cell Death Differ"},{"key":"R58-20260325","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bbrc.2019.03.158","article-title":"Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP\/TAZ signaling","volume":"512","author":"Wu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"R59-20260325","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling:Lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R60-20260325","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fphar.2017.00296","article-title":"Sphingosine 1-phosphate receptors:Do they have a therapeutic potential in cardiac fibrosis?","volume":"8","author":"Vestri","year":"2017","journal-title":"Front Pharmacol"},{"key":"R61-20260325","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3389\/fphar.2018.01504","article-title":"The role of S1P and the related signaling pathway in the development of tissue fibrosis","volume":"9","author":"Wang","year":"2018","journal-title":"Front Pharmacol"},{"key":"R62-20260325","doi-asserted-by":"crossref","first-page":"27343","DOI":"10.1074\/jbc.M116.740084","article-title":"TGF-\u03b2\/SMAD3 pathway stimulates sphingosine-1 phosphate receptor 3 expression:Implication of sphingosine-1 phosphate receptor 3 in lung adenocarcinoma progression","volume":"291","author":"Zhao","year":"2016","journal-title":"J Biol Chem"},{"key":"R63-20260325","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1128\/MCB.01465-07","article-title":"Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells","volume":"28","author":"Miller","year":"2008","journal-title":"Mol Cell Biol"},{"key":"R64-20260325","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00011-017-1037-3","article-title":"Sphingosine-1-phosphate is involved in inflammatory reactions in patients with Graves'orbitopathy","volume":"66","author":"Seo","year":"2017","journal-title":"Inflamm Res"},{"key":"R65-20260325","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1167\/iovs.16-20684","article-title":"Sphingosine-1-phosphate mediates fibrosis in orbital fibroblasts in graves'orbitopathy","volume":"58","author":"Ko","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R66-20260325","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1167\/iovs.18-25466","article-title":"CD40 enhances sphingolipids in orbital fibroblasts:Potential role of sphingosine-1-phosphate in inflammatory t-cell migration in graves'orbitopathy","volume":"59","author":"Pl\u00f6hn","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R67-20260325","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1167\/iovs.15-17863","article-title":"The role of sphingosine-1-phosphate in adipogenesis of graves'orbitopathy","volume":"57","author":"Kim","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R68-20260325","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1089\/thy.2018.0754","article-title":"Fingolimod improves the outcome of experimental graves'disease and associated orbitopathy by modulating the autoimmune response to the thyroid-stimulating hormone receptor","volume":"29","author":"Pl\u00f6hn","year":"2019","journal-title":"Thyroid"},{"key":"R69-20260325","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/iovs.63.6.7","article-title":"Potential therapeutic role of bone morphogenic protein 7 (BMP7) in the pathogenesis of graves'Orbitopathy","volume":"63","author":"Kim","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R70-20260325","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/cells9020280","article-title":"The role of bone morphogenetic protein 7 (bmp-7) in inflammation in heart diseases","volume":"9","author":"Aluganti Narasimhulu","year":"2020","journal-title":"Cells"},{"key":"R71-20260325","doi-asserted-by":"crossref","first-page":"e0147897","DOI":"10.1371\/journal.pone.0147897","article-title":"BMP-7 treatment increases M2 macrophage differentiation and reduces inflammation and plaque formation in Apo E-\/- Mice","volume":"11","author":"Singla","year":"2016","journal-title":"PLoS One"},{"key":"R72-20260325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1523-1755.2002.00103.x","article-title":"BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells","volume":"61","author":"Gould","year":"2002","journal-title":"Kidney Int"},{"key":"R73-20260325","doi-asserted-by":"crossref","first-page":"591275","DOI":"10.3389\/fphar.2020.591275","article-title":"Micellized protein transduction domain-bone morphogenetic protein-7 efficiently blocks renal fibrosis via inhibition of transforming growth factor-beta-mediated epithelial-mesenchymal transition","volume":"11","author":"Kim","year":"2020","journal-title":"Front Pharmacol"},{"key":"R74-20260325","doi-asserted-by":"crossref","first-page":"13507","DOI":"10.1111\/jcmm.15992","article-title":"Newly designed protein transduction domain (PTD)-mediated BMP-7 is a potential therapeutic for peritoneal fibrosis","volume":"24","author":"Kim","year":"2020","journal-title":"J Cell Mol Med"},{"key":"R75-20260325","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1038\/s41467-023-42754-w","article-title":"Structures of the interleukin 11 signalling complex reveal gp130 dynamics and the inhibitory mechanism of a cytokine variant","volume":"14","author":"Metcalfe","year":"2023","journal-title":"Nat Commun"},{"key":"R76-20260325","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-med-041818-011649","article-title":"Hiding in plain sight:Interleukin-11 emerges as a master regulator of fibrosis, tissue integrity, and stromal inflammation","volume":"71","author":"Cook","year":"2020","journal-title":"Annu Rev Med"},{"key":"R77-20260325","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature24676","article-title":"IL-11 is a crucial determinant of cardiovascular fibrosis","volume":"552","author":"Schafer","year":"2017","journal-title":"Nature"},{"key":"R78-20260325","doi-asserted-by":"crossref","first-page":"eaaw1237","DOI":"10.1126\/scitranslmed.aaw1237","article-title":"Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis","volume":"11","author":"Ng","year":"2019","journal-title":"Sci Transl Med"},{"key":"R79-20260325","doi-asserted-by":"crossref","first-page":"846106","DOI":"10.3389\/fendo.2022.846106","article-title":"IL-11 is elevated and drives the profibrotic phenotype transition of orbital fibroblasts in thyroid-associated ophthalmopathy","volume":"13","author":"Wu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R80-20260325","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/eji.200838535","article-title":"Induction, function and regulation of IL-17-producing T cells","volume":"38","author":"Mills","year":"2008","journal-title":"Eur J Immunol"},{"key":"R81-20260325","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"R82-20260325","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3389\/fimmu.2020.01558","article-title":"Biology of interleukin-17 and its pathophysiological significance in sepsis","volume":"11","author":"Ge","year":"2020","journal-title":"Front Immunol"},{"key":"R83-20260325","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/jcm13010164","article-title":"Targeting interleukin-17 as a novel treatment option for fibrotic diseases","volume":"13","author":"Sisto","year":"2023","journal-title":"J Clin Med"},{"key":"R84-20260325","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fgene.2015.00236","article-title":"Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs","volume":"6","author":"Khan","year":"2015","journal-title":"Front Genet"},{"key":"R85-20260325","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1210\/jc.2017-01349","article-title":"Regulation of orbital fibrosis and adipogenesis by pathogenic Th17 cells in graves orbitopathy","volume":"102","author":"Fang","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R86-20260325","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00417-012-2092-7","article-title":"Increased serum interleukin-17 in Graves'ophthalmopathy","volume":"250","author":"Kim","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R87-20260325","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1210\/jc.2016-1882","article-title":"IL-17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO","volume":"101","author":"Fang","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R88-20260325","first-page":"1007","article-title":"The role of interleukin-17A and NLRP3 inflammasome in the pathogenesis of graves'ophthalmopathy","volume":"13","author":"Lin","year":"2023","journal-title":"Life (Basel)"},{"key":"R89-20260325","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"R90-20260325","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling:Past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"R91-20260325","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2018.09.002","article-title":"IL-6:A cytokine at the crossroads of autoimmunity","volume":"55","author":"Jones","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"R92-20260325","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.7150\/ijbs.75876","article-title":"The role of IL-6 in fibrotic diseases:Molecular and cellular mechanisms","volume":"18","author":"Li","year":"2022","journal-title":"Int J Biol Sci"},{"key":"R93-20260325","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1089\/thy.2022.0254","article-title":"M1-Like macrophages modulate fibrosis and inflammation of orbital fibroblasts in graves'orbitopathy:Potential relevance to soluble interleukin-6 receptor","volume":"33","author":"Lu","year":"2023","journal-title":"Thyroid"},{"key":"R94-20260325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/08916939708996275","article-title":"High circulating IL-6 level in Graves'ophthalmopathy","volume":"25","author":"Moln\u00e1r","year":"1997","journal-title":"Autoimmunity"},{"key":"R95-20260325","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1210\/jc.2004-2239","article-title":"Gene expression profiling of orbital adipose tissue from patients with Graves'ophthalmopathy:A potential role for secreted frizzled-related protein-1 in orbital adipogenesis","volume":"90","author":"Kumar","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R96-20260325","doi-asserted-by":"crossref","first-page":"10792","DOI":"10.1038\/s41598-018-29113-2","article-title":"Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy","volume":"8","author":"Kishazi","year":"2018","journal-title":"Sci Rep"},{"key":"R97-20260325","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.4049\/jimmunol.175.2.1310","article-title":"IL-1 beta induces IL-6 expression in human orbital fibroblasts:Identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy","volume":"175","author":"Chen","year":"2005","journal-title":"J Immunol"},{"key":"R98-20260325","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1089\/105072501753210984","article-title":"Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves'ophthalmopathy","volume":"11","author":"Jyonouchi","year":"2001","journal-title":"Thyroid"},{"key":"R99-20260325","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14655","article-title":"Long-term outcomes in corticosteroid-refractory Graves'orbitopathy treated with tocilizumab","volume":"97","author":"Moi","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R100-20260325","first-page":"1194","article-title":"Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy","volume":"85","author":"Hiromatsu","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R101-20260325","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy:A randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R102-20260325","doi-asserted-by":"crossref","first-page":"1186105","DOI":"10.3389\/fendo.2023.1186105","article-title":"Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves'orbitopathy:An observational study","volume":"14","author":"Boutzios","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R103-20260325","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1136\/annrheumdis-2022-eular.4039","article-title":"AB1315 Sarilumab in patients with refractory graves'orbitopathy. Effectiveness and safety in a series of cases in clinical practice","volume":"81","author":"Moreira Navarrete","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R104-20260325","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nri.2016.40","article-title":"MicroRNAs as regulatory elements in immune system logic","volume":"16","author":"Mehta","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"R105-20260325","doi-asserted-by":"crossref","first-page":"952954","DOI":"10.3389\/fimmu.2022.952954","article-title":"Research progress on the pathogenesis of Graves'ophthalmopathy:Based on immunity, noncoding RNA and exosomes","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"R106-20260325","first-page":"1803","article-title":"Decreased microRNA-146a in CD4+T cells promote ocular inflammation in thyroid-associated ophthalmopathy by targeting NUMB","volume":"21","author":"Hu","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R107-20260325","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/ijmm.2022.5210","article-title":"Mechanisms and application strategies of miRNA146a regulating inflammation and fibrosis at molecular and cellular levels (Review)","volume":"51","author":"Liao","year":"2023","journal-title":"Int J Mol Med"},{"key":"R108-20260325","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1167\/iovs.16-19213","article-title":"Role of miR-146a in the regulation of inflammation in an in vitro model of Graves'orbitopathy","volume":"57","author":"Jang","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R109-20260325","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/bjophthalmol-2017-310723","article-title":"Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves'orbitopathy","volume":"102","author":"Jang","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R110-20260325","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1507\/endocrj.EJ14-0246","article-title":"Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves'ophthalmopathy","volume":"61","author":"Wei","year":"2014","journal-title":"Endocr J"},{"key":"R111-20260325","first-page":"1801","article-title":"MicroRNA-146a contributes to CD4(+) T lymphocyte differentiation in patients with thyroid ophthalmopathy","volume":"9","author":"Yang","year":"2017","journal-title":"Am J Transl Res"},{"key":"R112-20260325","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1055\/a-2161-5417","article-title":"Graves'orbitopathy models:Valuable tools for exploring pathogenesis and treatment","volume":"55","author":"Wang","year":"2023","journal-title":"Horm Metab Res"},{"key":"R113-20260325","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1089\/thy.2020.0088","article-title":"Apromising mouse model of graves'orbitopathy induced by adenovirus expressing thyrotropin receptor A subunit","volume":"31","author":"Zhang","year":"2021","journal-title":"Thyroid"},{"key":"R114-20260325","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1089\/thy.2023.0299","article-title":"Cre-loxP system-based mouse model for investigating Graves'disease and associated orbitopathy","volume":"33","author":"Bao","year":"2023","journal-title":"Thyroid"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-25-00057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:28:59Z","timestamp":1787837339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-25-00057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-25-00057","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"2025-04-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}